In the past week, SAVA stock has gone down by -4.35%, with a monthly gain of 6.65% and a quarterly surge of 130.65%. The volatility ratio for the week is 11.32%, and the volatility levels for the last 30 days are 8.61% for Cassava Sciences Inc. The simple moving average for the past 20 days is -1.42% for SAVA’s stock, with a 26.03% simple moving average for the past 200 days.
Is It Worth Investing in Cassava Sciences Inc (NASDAQ: SAVA) Right Now?
Moreover, the 36-month beta value for SAVA is -0.62. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SAVA is 42.38M and currently, short sellers hold a 37.55% of that float. On September 30, 2024, SAVA’s average trading volume was 3.51M shares.
SAVA) stock’s latest price update
Cassava Sciences Inc (NASDAQ: SAVA)’s stock price has dropped by -10.62 in relation to previous closing price of 31.87. Nevertheless, the company has seen a loss of -4.35% in its stock price over the last five trading days. fool.com reported 2024-09-27 that The biotech is paying $40 million not to acquire a drug or fund a development program, but to satisfy a regulator. The money is going toward a settlement with the Securities and Exchange Commission.
Analysts’ Opinion of SAVA
B. Riley Securities, on the other hand, stated in their research note that they expect to see SAVA reach a price target of $44. The rating they have provided for SAVA stocks is “Neutral” according to the report published on November 16th, 2022.
Cantor Fitzgerald gave a rating of “Neutral” to SAVA, setting the target price at $100 in the report published on July 15th of the previous year.
SAVA Trading at 11.22% from the 50-Day Moving Average
After a stumble in the market that brought SAVA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.50% of loss for the given period.
Volatility was left at 8.61%, however, over the last 30 days, the volatility rate increased by 11.32%, as shares sank -0.09% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +179.81% upper at present.
During the last 5 trading sessions, SAVA fell by -4.35%, which changed the moving average for the period of 200-days by +2.83% in comparison to the 20-day moving average, which settled at $28.89. In addition, Cassava Sciences Inc saw 26.54% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for SAVA
Current profitability levels for the company are sitting at:
- -58.69 for the present operating margin
- 0.42 for the gross margin
The net margin for Cassava Sciences Inc stands at -6.55. The total capital return value is set at -0.73. Equity return is now at value -8.35, with -6.97 for asset returns.
Currently, EBITDA for the company is -104.43 million with net debt to EBITDA at 1.51. When we switch over and look at the enterprise to sales, we see a ratio of 493.74. The receivables turnover for the company is 1.63for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.07.
Conclusion
To wrap up, the performance of Cassava Sciences Inc (SAVA) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
